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Summary:   
Shortly following introduction of PCV-13 in Switzerland, blood culture-proven pneumococcal sepsis 
accounted for 25% of community-acquired sepsis in children, with an 8% case fatality rate. Presence of 
meningitis and infection by serotype 3 were associated with severe disease.   
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Abstract  
Background: Population-based studies assessing the impact of pneumococcal conjugate vaccines (PCV) 
on burden of pneumococcal sepsis in children are lacking. We aimed to assess this burden following 
introduction of PCV-13 in a nationwide cohort study. 
Methods: The Swiss Pediatric Sepsis Study (09/2011-12/2015) prospectively recruited children <17 years 
of age with blood culture-proven sepsis due to Streptococcus pneumoniae, meeting criteria for systemic 
inflammatory response syndrome. Infection with vaccine serotype in children up to date with PCV 
immunization was defined as vaccine failure. Main outcomes were admission to pediatric intensive care 
unit (PICU) and length of hospital stay (LOS). 
Results: Children with pneumococcal sepsis (n=117) accounted for a crude incidence of 2.0 per 100,000 
children (95% CI 1.7-2.4) and 25% of community-acquired sepsis episodes. Case fatality rate was 8%. 42 
(36%) patients required PICU admission. Children with meningitis (29; 25%) were more often infected by 
serotypes not included in PCV (69% vs 31%; p<0.001). 16 (26%) of 62 children up to date with PCV 
immunization presented with vaccine failure, including 11 infected with serotype 3. In multivariable 
analyses, children with meningitis (OR 6.8; 95% C.I 2.4-19.3; p<0.001), or infected with serotype 3 (OR 
2.8; 95% C.I 1.1- 7.3; p=0.04) were more often admitted to PICU. Children infected with serotype 3 had 
longer LOS ( coefficient 0.2, 95% CI 0.1-1.1; p=0.01). 
Conclusions: The incidence of pneumococcal sepsis in children shortly after introduction of PCV-13 
remained substantial. Meningitis mostly due to non-vaccine serotypes and disease caused by serotype 3 
represented significant predictors of severity.   
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Abbreviations: CAP: community-acquired pneumonia; IPD: invasive pneumococcal disease; LOS: length 
of hospital stay; PCV: pneumococcal conjugate vaccine; PICU: pediatric intensive care unit; SIRS: 
systematic inflammatory response syndrome, ST: serotype. 
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Introduction 
 
Streptococcus pneumoniae is a leading cause of sepsis, meningitis and community-acquired pneumonia 
(CAP) resulting in significant mortality in children worldwide.[1, 2]  Invasive pneumococcal disease (IPD), 
defined as all clinical phenotypes in which S. pneumoniae was isolated from blood, cerebrospinal fluid, 
pleural fluid or any other normally sterile site by culture, antigen testing or molecular assays was 
significantly reduced after the implementation of pneumococcal conjugate vaccines (PCV). Surveillance 
studies conducted in the United States and in the United Kingdom reported 91% -97% effectiveness of 7-
valent PCV (PCV-7, Prevenar7®) and 13-valent PCV (PCV-13, Prevenar13®), respectively, among children 
< 5 years of age against IPD caused by serotypes included in PCV herein defined as vaccine serotypes [1, 
2].  A previous study [4] identified underlying co-morbidities as a major risk factor for IPD among 
children vaccinated with PCV-7 , whereas limited data  suggested an association between pneumococcal 
serotype 3 and death among children with bacteremic pneumonia [5]. For the incidence of 
pneumococcal disease most studies refer to IPD, while less is known on the rate of blood culture-proven 
sepsis, meeting the criteria for systemic inflammatory response syndrome (SIRS), herein defined as 
pneumococcal sepsis.  
There is a lack of recent population-based studies determining the burden and outcomes of 
pneumococcal sepsis in children. In Switzerland, the Federal Office of Public Health (FOPH) 
recommended the immunization of all children under 2 years of age (with a catch-up dose up to 5 years 
of age) with PCV-7 in 2006 followed by a switch to PCV-13 in 2011 [6]. In the present study, we assessed 
incidence, clinical presentation, risk factors for severity of pneumococcal sepsis in children using a 
nationwide prospective sepsis cohort [1, 2, 7]. 
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    Materials and Methods 
Participants and definitions 
The Swiss Pediatric Sepsis Study (SPSS) [8, 9] is a prospective national observational multicenter cohort 
study investigating blood culture-proven sepsis in children under 17 years of age from all ten major 
children’s hospitals in Switzerland from September 1, 2011, to December 31, 2015. Based on data of the 
mandatory hospital statistics, the 10 participating centers during the study period cared for 78% of all 
children < 17 years of age with an ICD-10 code for pathogen-specific sepsis admitted to a hospital in 
Switzerland, and for 98% of all children admitted to the intensive care unit with this code [9]. 
Details of the study design and the study protocol have been published elsewhere [9]. In brief, children 
with blood culture-proven sepsis meeting the criteria for SIRS, as defined by the 2005 pediatric 
consensus definition [7] at the time of blood culture sampling were included. SIRS required the presence 
of at least two of the following four criteria, one of which had to be abnormal temperature or leukocyte 
count: a core temperature > 38.5°C or < 36°C, Tachycardia, tachypnea, and abnormal white cell count. 
Severe sepsis was defined by the presence of cardiovascular or respiratory failure, or two or more other 
organ dysfunctions (hepatic, renal, hematologic, central nervous system). Septic shock was defined as 
sepsis in the presence of cardiovascular failure [7]. Ethics approval was obtained from all local ethics 
committees of participating centers, including a waiver from informed consent to record anonymized 
epidemiological data [9]. For the present study, only sepsis episodes due to S. pneumoniae bacteremia, 
were included. Admission to the pediatric intensive care unit (PICU) and length of hospital stay (LOS) 
were defined as outcomes.  
Collection of clinical information and specimens 
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Information on patient demographics, baseline characteristics and outcomes were collected 
prospectively [9]. For this analysis we grouped co-morbidities into the following categories: asplenia, 
sickle cell disease, and immunodeficiency, neurological, cardiac, respiratory and metabolic conditions, 
which represent distinct high-risk groups for IPD [6] and compared this group to so far healthy children 
without any known risk for IPD. The clinical focus was prospectively categorized into pneumonia, 
complicated pneumonia (any pneumonia with effusion), meningitis, other infection site (infections of 
bone and joint, ENT or skin), or primary bloodstream infection otherwise. Blood cultures were processed 
according to standard operating procedures of the local microbiology laboratory using an automated 
alert process.  
All S. pneumoniae isolates were serotyped at the national reference center for IPD in Berne, Switzerland, 
according to the standard procedure known as the Quellung reaction [10].  
Information on pneumococcal immunization status at the time of admission for sepsis was extracted 
from written personal vaccination cards. Vaccination with 7-valent (PCV-7, Prevenar®) or 13-valent 
pneumococcal conjugate vaccine (PCV-13, Prevenar 13®) was categorized in “up to date”, “not up to 
date” for age at sepsis or “unimmunized” along the criteria shown in Table 1 with protection being 
achieved 2 weeks after the 2nd dose [6]. Vaccine failure was defined as an infection with a vaccine 
serotype while being immunized fully up to date for age with PCV-7 or PCV-13.  
 
Incidence calculation 
To calculate the crude incidence of pneumococcal sepsis, we included only episodes recorded in full 
study years (2012-2015), as measured in the ten participating study centers. We calculated the age-
specific incidence of pneumococcal sepsis by dividing the annual number of blood culture-proven 
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pneumococcal sepsis episodes recruited in the study by the end-of-year resident population in 
Switzerland in the respective age-groups and age standardized it to the European standard population 
[9, 11].  We calculated the age-specific incidence of IPD in children in Switzerland (2012-2015) based on 
the number of IPD cases by age group using the same methodology. These data, which were collected in 
the frame of the mandatory notification of invasive pneumococcal diseases, were provided by the Swiss 
Federal Office of Public Health.  
 
 Statistical analyses 
The 2 test or Fisher’s exact test were used to compare categorical variables between groups as 
appropriate. Multivariable logistic regression was used to assess clinical, epidemiologic and socio-
demographic correlates of admission to the PICU. We derived medians and the interquartile range (IQR), 
used the Mann-Whitney test for comparisons of non-normally distributed continuous data, and used a 
transformation using the natural logarithm (ln) of LOS when performing multivariable linear regression.  
All available predictors including age, meningitis as clinical focus vs any other focus, infection with 
serotype 3 versus any other serotype, vaccine failure and the presence of any co-morbidity previously 
reported to be associated with adverse outcomes on the basis of the literature were included  a priori  in 
the initial models. Significant variables (p<0.05) were then added to multivariable models. In addition, 
an interaction variable between serotype 3 and vaccine failure was created given the potential 
interaction between both predictors with the outcomes of interest. All tests were two-sided and a p-
value < 0.05 was considered to be statistically significant. Data were analyzed using SPSS statistical 
software (version 20.0, SPSS Inc, Chicago, IL, USA). 
Results 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy1139/5270128 by U
niversitaetsbibliothek Bern user on 05 February 2019
 11 
 
Burden and presentation of pneumococcal sepsis 
In the 4.3-year study period, 117 children experiencing 118 pneumococcal sepsis episodes (one patient 
had recurrent pneumococcal infection) were recorded. S. pneumoniae accounted for 10% (118/1181) of 
all bacterial sepsis episodes in the Swiss Paediatric Sepsis Study (SPSS) and ranked fourth most frequent 
pathogen after Escherichia coli, Staphylococcus aureus and coagulase-negative staphylococci [9]. S. 
pneumoniae was the leading pathogen of sepsis among previously healthy children, causing 25% of 
community-acquired sepsis episodes (97/382). Among all children with pneumococcal sepsis, 57% were 
males. 83% were so far healthy without any risk while 20 (17%) suffered from an underlying disease at 
risk for IPD of whom 9 with an immune-compromising condition. Sixty children (51%) presented with 
pneumonia including 18 (15%) complicated by pleural effusion, 29 (25%) with meningitis, 19 (16%) with 
primary bloodstream infection and 9 (8%) with any other clinical focus. The median age was 3.6 years 
(interquartile range (IQR) 1.8-6.0). Meningitis was more common in infants than in older children 
(14/29; 48% vs. 10/88; 11%; Table 2). 
The crude incidence of blood culture-proven pneumococcal sepsis was 2.0 per 100’000 children (95% CI 
1.7 - 2.4), which translated into an age-standardized incidence of 2.1 per 100’000 children (95% CI 1.7 - 
2.5). It was highest in infants (6.7 per 100’000 (95% CI 4.2-10.1)) and toddlers (3.6 per 100’000 (95% CI 
2.7-4.8)) and decreased in older children (Figure 1).  
 
Sepsis severity and outcomes  
The median duration of hospital stay of children with pneumococcal sepsis was 9 days (IQR 4-14 days). 
Forty-two (36%) children were admitted to PICU of whom 22 (52%) required mechanical ventilation. 
Fourteen children (12%) presented with septic shock. Nine children died resulting in a case fatality rate 
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of 8%. Eight deaths were directly related to sepsis, and one child died due to an underlying metabolic 
condition with acute encephalopathy, which may have been triggered by sepsis. The fatal cases included 
7 previously healthy patients (median age 3.7 years (IQR 1.4-6.2)) of which 4 patients presented with 
meningitis (Table 2). 
 
Serotype distribution and immunization status  
Information on pneumococcal serotype was available in 112 of 117 (96%) children. The vaccine 
serotypes 3 (n=27; 24%), 19A and 7F (n=11; 10% each) were most frequently detected, followed by the 
non-vaccine serotypes 15 and 24 (n=7, 6% each). Sixty-four episodes (57%) were caused by PCV-13 
serotypes. Twenty of the 29 children (69%) with meningitis were infected with non-vaccine serotypes of 
whom 7 (35%) were diagnosed with serotype 15, which was not detected in children without meningitis. 
Seven (78%) of the 9 fatal sepsis episodes were due to infection with non-vaccine serotypes (Figure 2, 
Table 3). 
Children infected with vaccine serotypes were older than those infected with non-vaccine serotypes 
(median 4.7 versus 2.2 years; p<0.001). Ten children (5/64 infected with PCV serotypes, 5/48 infected 
with non-vaccine serotypes) were too young (< 130 days of life) to be protected by immunization with 
PCV. 
Data on history of immunization with PCV was available from 102/117 (87%) children with 
pneumococcal sepsis of whom 33 (32%) children with known serotype were unvaccinated. These 33 
unvaccinated children included 4/7 children (57%) with sepsis due to PCV-7 serotypes, 19/51 (37%) with 
sepsis due to a serotype contained in PCV-13 but not in PCV-7 and 10/44 (23%) with sepsis due to non-
vaccine serotypes. A higher rate of unvaccinated children infected by pneumococcal serotypes included 
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in PCV-13 but not in PCV-7 was recorded compared with those infected by pneumococcal non-vaccine 
serotypes (19/51 (37%) versus 10/44 (23%); p<0.001).  
A total of 62 children were immunized “up to date” for age with respect to time of introduction of PCV 
and age. Immunization failure was recorded in 16 episodes, including 11 episodes due to serotype 3, 
three due to 19A, and one each due to serotypes 14 and 6B (Table 3). All children with vaccine failure 
and sepsis with serotype 3 had received two priming and a PCV-13 booster dose.  
  
Predictors of admission to the PICU and LOS  
Children with meningitis were more likely to be admitted to PICU compared to those without meningitis 
(20/29; 69% versus 22/88, 25%, p<0.001; Table 1). Children with sepsis with serotype 3 represented 31% 
(13/42) of children requiring PICU compared to 20% (14/70 among pneumococcal sepsis episodes not 
requiring PICU, and the overall LOS was longer compared to children infected by any other serotype (14 
days (IQR 9-18.5) versus 7 days (IQR 3-12), p=0.009). In multivariable analyses the presence of 
meningitis (OR 6.8; 95% C.I 2.4-19.3 p<0.001) and sepsis by serotype 3 (OR 2.8; 95% C.I 1.1-7.3; p=0.04) 
represented significant independent predictors of admission to the PICU. In addition, children infected 
with serotype 3 ( coefficient 0.2, 95% CI 0.1-1.1; p=0.01) presented with a longer hospital stay 
compared to those infected with any other serotype (Table 4). 
 
 
 
Discussion 
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Our study demonstrates the ongoing burden of pneumococcal sepsis among children in 
Switzerland, shortly after the introduction of PCV-13. Over half of the episodes were caused by 
serotypes included in PCV-13, predominantly serotype 3.  
 In this nationwide prospective study conducted between 2011 and 2015, just after the 
switch from PCV-7 to PCV-13, S. pneumoniae accounted for 25% of community-acquired blood 
culture-proven sepsis episodes. The estimated 3 doses coverage with PCV-13 among children 
under 2 years of age in Switzerland ranged from 75 to 80% in this period [12]. Pneumococcal 
sepsis predominantly affected previously healthy children under 5 years of age (83%) without 
known risk factors for IPD similar to reports before the introduction of PCV-13 [9, 10]. Infants 
had a three times higher incidence of pneumococcal sepsis compared to older children and 
were more likely to suffer from meningitis. 
The severity of pneumococcal sepsis was substantial. More than a third of children required 
admission to PICU and 12% presented with septic shock. In addition to meningitis, infection with 
serotype 3 was a significant independent predictor for admission to the PICU. Over one third of PICU 
admissions was related to serotype 3, translating into prolonged LOS. The need for PICU admission and 
the presence of meningitis put these children at a substantially higher risk for long-term sequelae 
including neurodevelopmental delay [13]. While our study was not powered to detect differences in 
mortality, the reported case fatality rate (8%) was comparable to a recent large Australian and New 
Zealand pediatric sepsis cohort (reporting data between 2002 and 2013) [14] but amongst the highest, 
i.e. twice as high, as the mean case fatality rate 3.5% reported for IPD in Europe (data reported between 
1998 and 2008) [15].  These discrepancies are likely related to different case definitions. Most reported 
data refers to the epidemiology of IPD among which bacteremia in children may represent 40-50% [1], 
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not all fulfilling sepsis criteria. IPD  beside sepsis includes many non-septic children with pneumonia or 
arthritis while our study focused on blood culture-proven sepsis applying the 2005 Pediatric Sepsis 
Consensus Definitions [7] representing the most severe phenotype compared to all IPD.  
Pneumococcal serotypes contained in PCV-13, mostly serotype 3, were responsible for more 
than half of the pneumococcal sepsis episodes in our study. We observed a lower rate of children being 
immunized up to date with PCV in our cohort compared to national data (66% vs 75-80%) [6, 12] which 
may reflect a selection of susceptible unprotected individuals in our cohort. Importantly, our study was 
started in the first year of introduction of PCV-13 into the general vaccine schedule in Switzerland. In the 
study period, the incidence rates of IPD among children under 5 years of age in Switzerland (7.5 per 
100’000 children per year) [6] were similar to those given by US population-based reports (6.4 per 
100’000 children) [16] and higher compared to reports from the UK (4.1 per 100’000 children) [2]. These 
discrepancies likely result from differences in timing of PCV-13 introduction, PCV-13 catch-up policies, 
vaccination coverage, and the period during which surveillance studies were conducted. Between 2011 
and 2015 vaccination coverage rates with 3 doses of PCV-13 of up to 93.5% have been reported in the 
UK, compared to 75-80 % in Switzerland [12, 17]. Herd protection from PCV-13 was probably not yet 
achieved in our cohort unlike in the UK [17]. In addition, the inclusion of a large number of children who 
did not qualify for PCV vaccination because of their age (> 5 years) were not or (age < 5 months of age) 
not yet fully protected, or who did not follow the recommendations may account for this finding. Recent 
national surveillance data [6, 18] reported a 50% decrease in IPD among children under 5 years of age 
between 2009 and 2017, that may be increasing to 80-90% as seen in other countries [1, 2, 17], thus 
supporting the efficacy of PCV-13 vaccination. 
However, 11 of 16 (69%) vaccine failures were caused by infection with serotype 3, supporting 
previous reports on the low immunogenicity of PCV-13 for serotype 3 [5, 6]. All children with vaccine 
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failure infected with serotype 3 had received a PCV-13 booster dose. This finding warrants 
considerations for more effective vaccines and immunization schedules given the impact of serotype 3 
observed in our cohort. The importance of serotype 3 in pneumococcal sepsis is supported by 
experimental studies, demonstrating significant cortical necrosis and abscess formation in meningitis 
among rats infected with serotype 3 compared to those infected with serotype 1 [5, 19-22] and a 
systematic review [5] which reported increased case-fatality rates amongst children and adults with 
bacteremic community-acquired pneumonia infected with serotype 3 compared to serotype 14. 
The strengths of this study are the population-based design and detailed prospectively collected 
information including serotyping and vaccination status. Based on mandatory hospital statistics the 
study centers cared for 78% of all children with ICD-10 coded for pathogen-specific sepsis admitted to a 
hospital in Switzerland [9]. By comparing data on blood culture-proven pneumococcal sepsis from our 
prospective study cohort with administrative data on IPD provided by the Swiss Federal Office of Public 
Health, we estimated that 40% of IPD episodes were represented in the study. This estimate is in line 
with bacteremia representing 48% of IPD cases among children in the US [1]. In addition, clearly defined 
criteria for the inclusion of children with bacteremia and SIRS resulted in a population of patients with 
an unequivocal phenotype. Limitations refer to SIRS-based sepsis definitions[25, 26], which recently 
have been revised in the adult population [23, 24]. Finally, we cannot report on the impact of PCV 
vaccination on the burden of pneumococcal sepsis in Switzerland because of the lack of data before the 
introduction of PCV vaccination.  
  In conclusion, the burden of disease of pneumococcal sepsis among young, mostly 
previously healthy children, still remains significant in Switzerland shortly after the introduction PCV-13. 
Pneumococcal serotype 3 infections accounted for a substantial proportion of cases in our cohort, were 
commonly seen in up to date for age vaccinated children, and were associated with more severe 
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disease. Our data support the need for vaccines with better protection against serotype 3 as well as the 
need for ongoing surveillance of IPD, and sepsis in particular, as the burden of sepsis by pneumococcal 
serotypes not included in PCV already in this study is relevant.  
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Legends to figures  
 
Figure 1 
Black horizontal lines show the crude incidence of blood culture-proven pneumococcal sepsis during full 
study years (2012 – 2015) by age group, as measured in the ten participating study centers; x show the 
national incidence of all invasive pneumococcal disease in Switzerland for each age-group given (data 
provided by the Swiss Federal Office of Public Health). Vertical lines represent the 95% CIs around the 
point estimates for each age-group. 
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Figure 2  
Pneumococcal serotypes isolated from blood from children with pneumococcal sepsis. Information on 
serotypes was available from 112 of 117 sepsis episodes (serotype not available in 5 episodes). Sepsis in 
is indicated by grey bars, black bars illustrate episodes with sepsis and meningitis. 
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TABLE 1: Definitions for vaccination up to date for age with 7-valent or 13-valent pneumococcal conjugate vaccine 
 
Age groups Complete vaccination: up to date for age Vaccination not up to date for age 
Children <12 months of age From 2 weeks after the second dose and 
onwards 
Received ≥ 1 dose without meeting 
criteria for complete vaccination 
Children 12-15 months of age  ≥2 doses before 12 months of age 
 and/or from 2 weeks after the second dose 
and onwards, regardless of age when the 
doses were administered 
Received ≥ 1 dose without meeting 
criteria for complete vaccination 
Children >15 months of age and 
<24 months of age 
 ≥2 doses documented before 12 months of 
age  
AND 1 dose from 12 months of age            
       onwards administered ≥ 2 weeks ago 
Received ≥ 1 dose without meeting 
criteria for complete vaccination 
Children ≥24 months of age  ≥2 doses documented before 12 months of 
age AND 1 dose from 12 months of age 
onwards  administered ≥ 2 weeks ago 
 OR from 2 weeks after the second dose 
onwards when these 2 doses were 
administered from age 12 months onwards 
AND the second dose was administered ≥ 2 
Received ≥ 1 dose without meeting 
criteria for complete vaccination 
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weeks ago 
 OR ≥ 1 dose documented ≥24 months of 
age AND the first (or only) dose was 
administered ≥ 2 weeks ago 
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TABLE 2: Baseline characteristics and clinical outcomes of children presenting blood culture-proven pneumococcal sepsis 
 All patients 
N=117 
Meningitis 
N=29 
Non-meningitis 
N=88 
P values 
A)  Baseline characteristics  
 
Age; median years (IQRa) 3.6 (1.8-6.0)  1.7 (0.6-6.5)  3.8 (2.2-5.9)  0.385 
< 2 months; N (%) 6 (5.1)  2 (7)  4 (4.5)  <0.001 
2-12 months; N (%) 18 (15.4)  12 (41.4)  6 (6.8)  <0.001 
12 months-4 years; N (%) 50 (42.7)  6 (20.7)  44 (50.0)  0.009 
≥ 5 years; N (%) 43 (36.8)  9 (31.0)  34 (38.6)  0.503 
Gender; N male (%) 67 (57.3)  19 (65.5)  48 (54.5)  0.388 
Ethnicity; N caucasian (%) 92 (88.5)  24 (88.9)  68 (88.3)  0.247 
No underlying comorbidity; N (%) 97 (82.9)  26 (89.7)  71 (80.7)  0.145 
 
B) Clinical outcomes  
 
Severe sepsis; N (%) 27 (23.1)  12(41.4)  15 (17)  0.009 
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Septic shock; N (%) 14 (12)  5 (17.2)  9 (10.2)  0.331 
Death at 30 days of admission; N (%) 9 (8.1)  4 (14.3)  5 (6)  0.226 
Admission in PICU; N (%) 42 (36)  20 (69)  22 (25)  0.001 
Invasive ventilation; N (%) 22 (18.8)  8 (27.6)  14 (15.9)  0.260 
Length of stay in PICU; median days (IQR) 4 (1.5-10)  3 (1-6)  5 (2-10)  0.313 
Length of hospital stay; median days (IQRa) 9 (4-14)  10 (8.3-14.8)  7 (3.0-14)  0.210 
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                                       LEGEND  aIQR interquartile range; p-values compare children with pneumococcal sepsis with to those without meningitis; 
significant p values (P<0.05) are indicated in bold. Severe sepsis included in addition presence of cardiovascular organ dysfunction or acute respiratory 
distress syndrome or two or more other organ dysfunctions. Septic shock was defined as sepsis and cardiovascular organ dysfunction [1]. 
    
Table 3.   S. pneumoniae serotype distribution by immunization status in children with pneumococcal sepsis 
  
 
         
  Infection by vaccine serotype 
Infection by non-vaccine 
serotype unknown   Total 
 
Immunization status 
in 
PCV13 
in 
PCV7 
in PCV13 
 but not 
PCV7  ST 3 Non PCV13  
 
 
  Total    64   7  57 27 48  5 117 
 Up to date for age 
immunization failure*    16** 2 14 11   16 
     16  16 5 29 1 46 
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Up to date for age as 
recommended but not 
against serotype of sepsis    
  
Not up to date for age as  
recommended       3 1 2 1 5   1  9 
  
 No immunization    23 4 19 9 10   3  36 
  
 No data on immunization     6 0 6 1 4   10 
 
       
*immunization failure (as defined in table 1): infection with vaccine serotype and PCV immunized up to date for age.   
**serotype 3: n=11, 19A: n=3, serotype 14: n=1; serotype 6B: n=1 
Note: 32 children had a pneumococcal sepsis due to a serotype included in PCV and were immunized as recommended. Among those, 16 were immunized 
up to date for age with PCV against the serotype causing sepsis and were counted as vaccine failures. The other 16 children were immunized as 
recommended with PCV but at time of sepsis were not protected against the serotype causing sepsis (received PCV7 while the serotype causing sepsis was 
only included in PCV13 but not in PCV7).  
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TABLE 4: Predictors of admission in the PICU and length of hospital stay for children with pneumococcal sepsis 
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 PICU admission (n=42) Length of hospital stay (n= 117 ) 
 Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis 
OR  
(95 %C.I) 
P value OR 
(95 %C.I) 
P value ß coefficient (95 
%C.I) 
P value ß coefficient  
(95 %C.I) 
P value 
Infants (< 12 months of age) 
vs older children 
2.6 
(1.04, 6.5) 
0.04 1.4 
(0.5,4.2) 
0.559 0.1 
(-0.2, 0.8) 
0.225 0.1  
(-0.2, 0.8) 
0.258 
Meningitis vs no meningitis 6.7 
(2.6, 16.8) 
<0.001 6.8  
(2.4,19.3) 
<0.001 0.2 
(0.04,0.9) 
0.034 0.2 
(-0,05,0.9) 
0.08 
Infection with serotype 3  
vs any other serotype 
1.8 (0.8, 4.3) 0.192 2.8 
(1.1,7.3) 
0.04 0.2  
(0.005,0.9) 
0.03 0.2 
(0.1,1.1) 
0.01 
Vaccine failure in children PCV 
immunized up to date for age (1) 
0.8                
(0.2, 2.2) 
0.637 - - 0.01              
(-0.05, 0.6) 
0.923 - - 
Interaction variable 
serotype 3x vaccine failure* 
1.4 
(0.4, 5.1) 
0.568 - - 0.09 
(-0.4, 1.0) 
0.353 - - 
Presence of any co-morbidity 0.4  
(0.1, 1.3) 
0.142 - - 0.032  
(-0.1, 0.2) 
0.735 - - 
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(1) Infection with vaccine serotype and immunized up to date for age with PCV-7 or PCV-13 vs infected with non-vaccine serotype or with a vaccine 
serotype AND not immunized at all 
*   An interaction effect occurs when the effect of one variable depends on the value of another variable. As vaccine failure might depend on serotype 
3, 
     an interaction variable between serotype 3 and vaccine failure was created  
      OR: Odds ratio; C.I: Confidence interval 
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